Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Njordis is a venture capital and advisory firm founded in 2022, focused on investing in seed-to-venture-stage technology companies. The firm operates from Europe, with a particular emphasis on the DACH region (Germany, Austria, Switzerland) and the Nordic countries. Njordis combines its investment activities with a publishing and content provision role, enhancing its presence in the investment landscape.
Founded by a team with advisory board mandates at multinational organizations, Njordis leverages its extensive network and expertise to support portfolio companies. The firm emphasizes a philosophy of 'positive progress for humanity,' aiming to back innovative solutions that address pressing technology and business challenges.
As of now, Njordis is actively engaged in the venture capital space, although specific details regarding its assets under management (AUM) or fund size have not been disclosed. The firm is positioned to make a significant impact in the technology investment sector, particularly in healthcare and biotechnology.
Njordis invests primarily in technology companies at the seed to venture stages, with a focus on sectors such as healthcare, biotechnology, quantum technologies, and blockchain. The firm typically writes checks ranging from €50,000 to €500,000, although it may participate in larger funding rounds alongside institutional partners. This flexibility allows Njordis to adapt to the needs of its portfolio companies while also enhancing its investment strategy.
The firm operates with an industry- and technology-agnostic approach, emphasizing its commitment to supporting innovative solutions that promote positive societal impact. Njordis seeks founders who are not only driven but also aligned with its philosophy of positive progress for humanity. The firm’s investment strategy includes providing advisory services that assist with growth, scaling, business model development, and market entry.
What are Njordis's investment criteria?
Njordis focuses on seed to venture-stage technology companies, particularly in healthcare, biotechnology, quantum technologies, and blockchain. The firm looks for innovative solutions that align with its philosophy of positive progress for humanity.
How can I pitch Njordis?
Founders interested in pitching to Njordis should prepare a detailed presentation that outlines their business model, market potential, and alignment with Njordis's investment thesis. While specific application channels are not disclosed, a warm introduction through mutual connections may enhance the chances of engagement.
What makes Njordis different from other venture capital firms?
Njordis combines its investment activities with advisory services, providing portfolio companies with support in growth, scaling, and market entry. The founders' involvement in advisory boards of multinational organizations adds significant value to their portfolio companies.
What is Njordis's geographic focus?
Njordis primarily invests in Europe, with a strong emphasis on the DACH region and Nordic countries. This geographic focus allows the firm to leverage its local expertise and network effectively.
What is the typical check size for Njordis?
Njordis typically invests between €50,000 and €500,000 in its portfolio companies. The firm may also participate in larger funding rounds alongside institutional partners.
What kind of post-investment support does Njordis provide?
Njordis offers extensive advisory services to its portfolio companies, assisting with business model development, market entry strategies, and addressing technology challenges. The firm's founders actively engage with portfolio companies to provide mentorship and guidance.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.